文献速递炎症性肠病

乌司奴单抗与维得利珠单抗在抗TNF治疗失败的克罗恩病中的短期与长期疗效比较

Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
PubMed 文献 · Aliment Pharmacol Ther · 2021-04-28

本研究比较了乌司奴单抗与维得利珠单抗在抗TNF治疗失败的克罗恩病患者中的短期和长期疗效。共纳入312例患者(乌司奴单抗224例,维得利珠单抗88例),经倾向性评分匹配分析显示,乌司奴单抗在第54周无激素临床缓解率和第14周深度缓解率均优于维得利珠单抗,且原发无应答率和因治疗失败停药风险更低。

要点

  • 抗TNF失败的克罗恩病患者中,乌司奴单抗第54周无激素临床缓解率高于维得利珠单抗。
  • 乌司奴单抗第14周深度缓解率更高,原发无应答率和长期停药风险更低。
  • 乌司奴单抗失败预测因素包括复杂表型和抗TNF原发无应答。

核心结论

  • 在抗TNF治疗失败的克罗恩病患者中,乌司奴单抗在早期和长期疗效方面均优于维得利珠单抗。

研究设计与样本

  • 来自两个转诊中心的所有接受乌司奴单抗或维得利珠单抗治疗且既往暴露于至少一种抗TNF药物的克罗恩病患者被纳入研究。
  • 共纳入312例患者,其中乌司奴单抗组224例,维得利珠单抗组88例。
  • 采用倾向性评分匹配分析使两组具有可比性。

主要发现

  • 倾向性评分分析后,乌司奴单抗第54周无激素临床缓解率高于维得利珠单抗(49.3% vs 41.2%,P = 0.04)。
  • 乌司奴单抗第14周深度缓解率高于维得利珠单抗(25.9% vs 3.8%,P = 0.02)。
  • 乌司奴单抗原发无应答率低于维得利珠单抗(6.7% vs 14.8%,P = 0.034)。
  • 乌司奴单抗因治疗失败长期停药风险低于维得利珠单抗(HR = 1.53 [1.04-2.07],P = 0.029)。
  • 乌司奴单抗失败预测因素包括复杂表型(OR = 2.35 [1.31-4.22],P = 0.004)和抗TNF原发无应答(OR = 2.55 [1.27-5.12],P = 0.008)。

关键数值与推荐

  • 主要终点为第54周无激素临床缓解,定义为克罗恩病活动指数<150。
  • 深度缓解在第14周评估,定义为无激素临床缓解且粪便钙卫蛋白<100 µg/g。
  • 维得利珠单抗在年龄>35岁(OR = 0.41 [0.19-0.87])、非复杂表型(OR=0.42 [0.18-0.96])、无既往肠切除(OR = 0.49 [0.24-0.96])和基线无激素使用(OR=0.47 [0.23-0.97])的患者中疗效低于乌司奴单抗。

临床怎么用

  • 对于抗TNF治疗失败的克罗恩病患者,乌司奴单抗可能是一个更有效的治疗选择。
  • 具有复杂表型或抗TNF原发无应答的患者使用乌司奴单抗时需注意失败风险。
  • 维得利珠单抗在特定亚组(如年龄>35岁、非复杂表型等)中疗效相对较低,选择时需考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The best option between vedolizumab and ustekinumab after anti-tumour necrosis factor (TNF) failure remains unclear in Crohn's disease. AIMS: To compare the short- and long-term effectiveness of vedolizumab and ustekinumab in Crohn's disease patients with prior anti-TNF exposure. METHODS: All Crohn's disease patients treated with ustekinumab or vedolizumab after exposure to at least one anti-TNF agent were included from two referral centres. Primary endpoint was corticosteroid-free clinical remission defined as Crohn's disease activity index <150 at week 54. Deep remission (corticosteroid-free clinical remission and faecal calprotectin <100 µg/g) was assessed at week 14. Propensity-matched analyses were applied to make the two groups comparable. RESULTS: Overall, 312 patients (ustekinumab = 224 and vedolizumab = 88) were included. After propensity score analysis, ustekinumab was more effective to achieve corticosteroid-free clinical remission at week 54 (49.3% vs 41.2%, P = 0.04) and deep remission at Week 14 (25.9% vs 3.8%, P = 0.02) than vedolizumab. The rate of primary nonresponders (6.7% vs 14.8%, P = 0.034) and the long-term risk of drug discontinuation due to therapeutic failure (HR = 1.53 [1.04-2.07], P = 0.029) were lower in patients treated with ustekinumab compared with vedolizumab. Predictors of ustekinumab failure were complicated phenotype (odds ratio [OR] = 2.35 [1.31-4.22]; P = 0.004) and anti-TNF primary non-response (OR = 2.55 [1.27-5.12]; P = 0.008). We did not find any predictor of corticosteroid-free clinical remission in patients treated with vedolizumab. Vedolizumab was less effective than ustekinumab in patients >35 years old (OR = 0.41 [0.19-0.87]), with noncomplicated phenotype (OR=0.42 [0.18-0.96]), no prior bowel resection (OR = 0.49 [0.24-0.96]), and no steroids at baseline (OR=0.47 [0.23-0.97]). CONCLUSION: Ustekinumab was more effective to achieve early and long-term effectiveness than vedolizumab in Crohn's disease patients who previously failed response to anti-TNF agents.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Manlay L, Boschetti G, Pereira B, et al. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy. Aliment Pharmacol Ther. 2021. PMID: 33909920. doi:10.1111/apt.16377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。